Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Has announcements × Crizotinib × Clear all

Phase

Status

Completed 4 Active not recruiting 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1 CNS 1

Conditions

Neuroblastoma 1 Neoplasms 1 Lymphoma 1

Interventions

TIC10 compound 3 trastuzumab deruxtecan 2 umbralisib 1 ublituximab 1 duvelisib 1 blinatumomab 1 belumosudil 1 Rituximab 1 KD025 1 Crizotinib 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Pfizer

Phase 1 Terminated

44 enrolled 22 charts 1 FDA

Lymphoma, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡